Compare GGR & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | RPTX |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Taiwan | Canada |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.6M | 92.4M |
| IPO Year | N/A | 2020 |
| Metric | GGR | RPTX |
|---|---|---|
| Price | $3.38 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 22.5K | ★ 1.5M |
| Earning Date | 02-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,211,000.00 | $11,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.15 | $3,233.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.89 |
| 52 Week High | $10.15 | $2.66 |
| Indicator | GGR | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 65.65 |
| Support Level | $2.96 | $2.52 |
| Resistance Level | $3.37 | $2.61 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 86.75 | 29.63 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.